BofA Merrill Lynch Reiterates on AbbVie, Raises PO

In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert reiterated a Buy rating on AbbVie (NYSE: ABBV ), raising its price target from $53.00 to $56.00. According to the report, in light of recent positive trial results and a survey published by BofA's biotech team,